Referred to the House Committee on Energy and Commerce.
The Prescription Freedom Act of 2025 repeals the FDA’s federal authority under 21 U.S.C. 353(b) to require that drugs be dispensed only by prescription, effective six months after enactment. After that date, federal references to prescriptions defer to applicable State law and to state requirements as determined by responsible federal officials.
Progressives emphasize national safety standards; conservatives emphasize state control and choice.
Relative to its intended legislative type, this bill is a straightforward statutory repeal with specific legal mechanics (effective date, deeming language, and a narrow exception) but limited supporting detail on implementation, fiscal impact, safety boundaries, and oversight.
The Prescription Freedom Act of 2025 repeals the FDA’s federal authority under 21 U.S.C. 353(b) to require that drugs be dispensed only by prescription, effective six months after enactment.
After that date, federal references to prescriptions defer to applicable State law and to state requirements as determined by responsible federal officials.
An exception allows the HHS Secretary to retain the FDA’s prescription authority for drugs intended to terminate a pregnancy.
Broad, contentious federal deregulation lacking bipartisan safeguards; substantial implementation, safety, and legal obstacles.
Relative to its intended legislative type, this bill is a straightforward statutory repeal with specific legal mechanics (effective date, deeming language, and a narrow exception) but limited supporting detail on implementation, fiscal impact, safety boundaries, and oversight.
Progressives emphasize national safety standards; conservatives emphasize state control and choice.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize national safety standards; conservatives emphasize state control and choice.
Likely opposed overall because removing the FDA’s prescription authority reduces federal public-health safeguards and uniform safety standards.
The abortion-drug exception is positive but does not address broader safety, oversight, or access equity concerns.
They would worry about increased health risks, uneven state protections, and consumer confusion.
Cautiously skeptical: values the deregulatory intent and state flexibility but worries about public-health consequences and legal confusion.
Sees potential cost savings and access benefits but wants clear transition plans, federal safeguards where necessary, and clarity on interactions with other federal laws.
Generally supportive because the bill reduces federal regulatory power, increases individual choice, and defers to states.
The abortion-drug exception is acceptable to many conservatives who prefer preserving federal controls on abortion-related products.
They will welcome deregulation and market-based access improvements.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Broad, contentious federal deregulation lacking bipartisan safeguards; substantial implementation, safety, and legal obstacles.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize national safety standards; conservatives emphasize state control and choice.
Broad, contentious federal deregulation lacking bipartisan safeguards; substantial implementation, safety, and legal obstacles.
Relative to its intended legislative type, this bill is a straightforward statutory repeal with specific legal mechanics (effective date, deeming language, and a narrow exception) but limited supporting detail on implem…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.